Fresh data on protein interactions in Alzheimer’s disease

Professor Sara Linse will highlight the Fluidity One-W as an influential technology for protein interaction analysis during plenary lecture at FEBS 2019.
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.
Fluidic Analytics’ diffusional sizing technology has been influential in a recent study that investigates protein binding and self-assembly in Alzheimer’s disease. This work will be presented by Professor Sara Linse of Lund University, Sweden, during the FEBS/EMBO Women in Science Award plenary lecture at FEBS 2019, Krakow, Poland (Sunday 7 July at 2 pm). Her work on the mechanism of amyloid β aggregation and the role of inhibitors demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.
Fluidic Analytics will host an extended Q&A session with Professor Linse at their booth (number 7) at 3 pm following her plenary talk. Visitors to the Fluidic Analytics booth will also be able to have an early look at the Fluidity One-W before its official launch later this year. This instrument has the ability to assess on-target protein interactions in solution and in crude biological backgrounds – opening up the possibilities for detailed analysis of proteins in their near-native states and natural environments. The system is easy-to-use, and based on the well-understood relationship between size and diffusion rate, providing researchers with true confidence in the quality and accuracy of their data.
Professor Sara Linse, Department of Biochemistry and Structural Biology, Lund University commented: “During our research into protein amyloid formation, we have used many different techniques for assessing protein interactions – all with different limitations and advantages. With diffusional sizing, we were able to confidently generate accurate and complete in-solution data using amyloid proteins to connect stoichiometry and binding affinities with protein self-assembly. The data we will present at FEBS 2019 could provide key insights for novel therapeutic approaches in Alzheimer’s disease. The Fluidity One-W has contributed significantly to this detailed understanding.”
With applications ranging from neurobiology and cell signalling to drug discovery, the potential impact of diffusional sizing in fundamental scientific research is vast and spans many research areas. Dr Sean Devenish, Head of R&D at Fluidic Analytics explained: “The unique capabilities of the Fluidity One-W position it as the only viable option for analysing difficult-to-study proteins, like amyloid fibrils, in solution. Researchers gain the best insight into what their protein of interest is interacting with, and how, even in complex backgrounds such as crude lysates. The technology is opening up many new avenues of research into protein interactions and expanding the systems that can be studied, and Professor Linse’s recent work is a great example of what’s possible with this new approach to protein analysis.”
Related News
-
News Rebuilding the United States' pharma infrastructure – CPHI North America 2023 preview
As we prepare for CPHI North America from April 25–27 in Philadelphia, USA, CPHI Online caught up with some of the track sponsors to discuss how the show connects vital players within the North American pharmaceutical landscape. ... -
News Digital-first experimental approach to optimise drug formulations
Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ a... -
News To recruit or to retain - where is the pharma talent going?
Discover how the pharmaceutical workforce has evolved past the pandemic, and the challenges faced by the pharma industry during a talent acquisition and retention crisis. -
News NextPharma acquisition of chewable tablet manufacturing site from Takeda complete
NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda. -
News Doctors Without Borders demands transparency from GSK on licensing agreements for preventative HIV treatment
GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker. -
News Thermo Fisher Scientific and UCSF open cell therapy manufacturing facility
In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Innovation in Drug Delivery & Portfolio Renovation with Sofgen Pharmaceuticals
The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, w...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance